ESMO 2023 | REGOMA-OS: a real-world study into the use of regorafenib for patients with recurrent glioblastoma

Giuseppe Lombardi, MD, PhD, Veneto Institute of Oncology, Padua, Italy, discusses the real-world REGOMA-OS (NCT04810182) study onducted after the successes of the Phase II REGOMA (NCT02926222) trial, evaluating the activity and safety profile of regorafenib as a monotherapy for patients with recurrent glioblastoma. Dr Lombardi elaborates on the results of the real-world study vs REGOMA, highlighting similarities in median overall-survival (OS) and progression-free survival (PFS) of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.